A quarter of people with HCV initially refused access to sofosbuvir/lepidasvir

A quarter of people with HCV initially refused access to sofosbuvir/lepidasvir … Treatment of HCV infection has been revolutionised by the development of direct-acting antiviral (DDA) agents. Compared to traditional therapy with pegylated interferon/ribavirin, treatment with DDAs is associated with … Continue reading

Biotron develops combined HIV-1 and HCV treatment

Biotron develops combined HIV-1 and HCV treatment Biotron Limited, which develops innovative treatments for viral diseases that have unmet medical needs, recently released information about its leading drug, a combined treatment for HIV-1 and Hepatitis C virus (HCV). BIT225 shows … Continue reading

Gilead Sciences Inc. (NASDAQ:GILD) Deals with its HCV Drug Issue

Gilead Sciences Inc. (NASDAQ:GILD) Deals with its HCV Drug Issue Gilead Sciences Inc. (NASDAQ:GILD) has taken the decision to limit the number of patients it admits to its support path patient assistance program. The decision only affects those patients seeking … Continue reading

Hepatitis C treatment could halve HCV transmission among gay men in UK over

Hepatitis C treatment could halve HCV transmission among gay men in UK over … To estimate the potential effect of treatment on HCV incidence and prevalence in MSM in the United Kingdom, Natasha Martin of the University of California San … Continue reading

Gilead Sciences, Inc. (GILD) Leads The HCV Race Despite Competition From

Gilead Sciences, Inc. (GILD) Leads The HCV Race Despite Competition From … AbbVie launched its hepatitis C drug, Viekira Pak, with the intent to cannibalize Gilead's hepatitis C drug sales, as evident from the fact that the company immediately went … Continue reading